Global evidence on molecular adsorbent recirculating system uses for trauma-induced acute liver failure: A scoping review.

Marcelo Augusto Fontenelle Ribeiro Junior, Rafael Dib Possiedi, Husna Irfan Thalib, Lucas Fontenelle Vieira, William A Teeter, Thomas M Scalea
{"title":"Global evidence on molecular adsorbent recirculating system uses for trauma-induced acute liver failure: A scoping review.","authors":"Marcelo Augusto Fontenelle Ribeiro Junior, Rafael Dib Possiedi, Husna Irfan Thalib, Lucas Fontenelle Vieira, William A Teeter, Thomas M Scalea","doi":"10.5492/wjccm.117566","DOIUrl":null,"url":null,"abstract":"<p><p>The molecular adsorbent recirculating system (MARS) is an extracorporeal liver support therapy used in acute liver failure, including cases related to trauma; however, evidence supporting its use in trauma-induced liver dysfunction remains limited. This scoping review aimed to systematically map the available literature on the use of MARS therapy in trauma patients and to identify knowledge gaps to guide future research. The review was conducted according to Joanna Briggs Institute methodology and reported in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines, with a protocol prospectively registered in the Open Science Framework. Six electronic databases and two clinical trial registries were searched through December 2025, with additional backward citation tracking. Four observational studies met inclusion criteria, comprising 247 patients treated with MARS therapy, of whom only 11 had confirmed trauma-related acute liver failure. No randomized controlled trials were identified. Trauma-specific outcomes were inconsistently reported, and adverse events were not uniformly documented. Survival and liver function recovery varied across studies, and methodological heterogeneity precluded reliable assessment of clinical effectiveness or safety. Current evidence remains sparse and insufficient to support routine clinical use in trauma populations.</p>","PeriodicalId":66959,"journal":{"name":"世界危重病急救学杂志(英文版)","volume":"15 3","pages":"117566"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548154/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界危重病急救学杂志(英文版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5492/wjccm.117566","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The molecular adsorbent recirculating system (MARS) is an extracorporeal liver support therapy used in acute liver failure, including cases related to trauma; however, evidence supporting its use in trauma-induced liver dysfunction remains limited. This scoping review aimed to systematically map the available literature on the use of MARS therapy in trauma patients and to identify knowledge gaps to guide future research. The review was conducted according to Joanna Briggs Institute methodology and reported in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines, with a protocol prospectively registered in the Open Science Framework. Six electronic databases and two clinical trial registries were searched through December 2025, with additional backward citation tracking. Four observational studies met inclusion criteria, comprising 247 patients treated with MARS therapy, of whom only 11 had confirmed trauma-related acute liver failure. No randomized controlled trials were identified. Trauma-specific outcomes were inconsistently reported, and adverse events were not uniformly documented. Survival and liver function recovery varied across studies, and methodological heterogeneity precluded reliable assessment of clinical effectiveness or safety. Current evidence remains sparse and insufficient to support routine clinical use in trauma populations.

分子吸附剂再循环系统用于创伤性急性肝衰竭的全球证据:范围综述。
分子吸附剂再循环系统(MARS)是一种体外肝支持治疗,用于急性肝衰竭,包括与创伤有关的病例;然而,支持其用于外伤性肝功能障碍的证据仍然有限。本综述旨在系统地绘制关于创伤患者使用MARS治疗的现有文献,并确定知识空白,以指导未来的研究。该综述按照Joanna Briggs研究所的方法进行,并按照系统综述的首选报告项目和范围综述的元分析扩展指南进行报告,该方案有望在开放科学框架中注册。截至2025年12月,检索了六个电子数据库和两个临床试验注册库,并进行了额外的反向引文跟踪。4项观察性研究符合纳入标准,包括247例接受MARS治疗的患者,其中只有11例确诊为外伤性急性肝衰竭。未发现随机对照试验。创伤特异性结果的报道不一致,不良事件的记录也不一致。生存率和肝功能恢复在不同的研究中有所不同,而且方法学的异质性妨碍了对临床有效性或安全性的可靠评估。目前的证据仍然稀少,不足以支持创伤人群的常规临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
216
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书